Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
USD 690 In stock
USD 990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NUPPd2V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDESnRKSzVyPUCuNVLjiIoEsfMAjVAvODFizszN MV6yOVk3ODJ6Mh?=
KellyCis83 M3jDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[4TXVKSzVyPUCuNVbjiIoEsfMAjVAvODJizszN NXqwSpQ3OjV7NkCyPFI>
SK-N-AS NYn2WYhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rNb2lEPTB;MD6yOQKBkcLz4pEJNE4xOyEQvF2= NWrDSZZxOjV7NkCyPFI>
SK-N-ASCis24 MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fwc2lEPTB;MD61O-KBkcLz4pEJNE4yOSEQvF2= MVuyOVk3ODJ6Mh?=
U87 M3jXTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP0SHB3OC13MDFOwG0> NVjOXm1XPDhiaB?= M3izfIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nlic3nsbYJqdmmw NYfDdVRSOjV5NUCyO|M>
HCT116 NISzOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LmOlAvPS1{LkWg{txO M{TuXVQ5yqCqwrC= MYLJR|UxRTFwN{RCpOKyyqByLkKxxsDPxE1? MonkNlU4PDZ5NkO=
HT-29 NETGZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCwMlUuOi53IN88US=> NYLzZVJjPDkEoHlCpC=> NU\vcWQ3UUN3ME23MlLDqMLzwrCxMlA1yqEQvF2= MVmyOVc1Pjd4Mx?=
Caco2 Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX76U3hsOC53LUKuOUDPxE1? NH7XPWw1QMLiaNMg MVvJR|UxRTdwMkdCpOKyyqBzLk[4xsDPxE1? MV6yOVc1Pjd4Mx?=
COLO 205 M{Ho[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vaXVAvPS1{LkWg{txO NECyVmM1QMLiaNMg MofJTWM2OD1zLk[xxsDDucLiMD6wNuKh|ryP NXzhfmJmOjV5NE[3OlM>
SW480 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6wMlUuOi53IN88US=> MY[0POKhcMLi M13j[mlEPTB;ND65NuKhyrIEoECuN|PDqM7:TR?= M3jP[FI2PzR4N{[z
HEK293T NI\lfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:xMVUh|ryP NXXVcIJZPDkEoHlCpC=> NV7ocHZZUUN3ME2yMlQzyqEEsdMgNE4xPcLizszN NYLQdnRYOjV5NE[3OlM>
Hep3B  M2LhNGZ2dmO2aX;uJGF{e2G7 NWPUZ5U2OTBizszN MmHjOFjDqGkEoB?= Mk\RdoVlfWOnczD0bIUh\W6qYX7jbY5oKGWoZnXjeEBw\iCETWCtOi=> NGLLN|MzPTZ|M{W2OC=>
Hep3B  Mn;NSpVv[3Srb36gRZN{[Xl? M1\zXVAvOS1zMDFOwG0> NWi0dpYzOjRiaB?= MmPid5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBp\XClaXTpckBuWk6D NWHL[W9EOjV4M{O1OlQ>
HEK293 NGnHfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXvWW84UUN3ME23MlE1yqEEsdMgNE4{PsLizszN MlzkNlU3ODNzMkK=
DU145 M2\oVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17OcWlEPTB;Mj6yPOKhyrIEoECuNFTDqM7:TR?= MY[yOVYxOzF{Mh?=
HCT15 NGLFVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorETWM2OD1yLkixxsDDucLiMD6wNeKh|ryP MXmyOVYxOzF{Mh?=
T47D MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfXTWM2OD1|LkG4xsDDucLiMD6xNeKh|ryP MonGNlU3ODNzMkK=
SMMC-7721 NXfofFRTTnWwY4Tpc44hSXO|YYm= NUKzT|RQPDBizszN NV;qfpppPDhiaB?= MnjvSG1UVw>? NFG4eXBqdmS3Y3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdg>? M3XuNVI2PTR2M{[x
MDA-MB-231 NGjVPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHycWo4OsLiaB?= M1XzZmlEPTB;MkGuNuKhyrIEoESuNuKh|ryP NXvHZ2MxOjV2OE[yNVk>
MCF-7 NWXjU3FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3pbpY4OsLiaB?= MojsTWM2OD1zMD65xsDDucLiMj6xxsDPxE1? MnPzNlU1QDZ{MUm=
Jurkat MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7sO|LDqGh? NYfOVlZXUUN3ME2xMlLDqMLzwrCxMlXDqM7:TR?= MYiyOVQ5PjJzOR?=
HeLa NYfWe|RsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ry[VczyqCq MoPDTWM2OD1|LkpCpOKyyqB{LkRCpO69VQ>? Mk[1NlU1QDZ{MUm=
MCF7  NF[xe|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVe1MVExOCEQvF2= NX3sUYc5PyCm M4[z[IlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmDXNlU1PzJ4MUm=
K562 Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzjc5A4OsLiaB?= MX3JR|UxRTBwMkpCpO69VQ>? NVqyWXp2OjV{OEK2OVM>
K/VP.5 M1S2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3GZmtTPzMEoHi= MWnJR|UxRTRwOdMg{txO NVTTOlFIOjV{OEK2OVM>
SH-EP  NIG0cWhHfW6ldHnvckBCe3OjeR?= NWjMVoN6OjEEoN88[{9udA>? MlLWNlTDqGh? Ml[wbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIVv\G:pZX7veZMhTEWSUB?= NUP6V|M4OjV{NkG5PFE>
SCC25 MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPHUmJUOjUEoHi= NXzRUIxHUUN3ME20N{4{yqEEsdMgNU4yOsLizszN NYrDNY9lOjV{MkC3Nlk>
CAL27 Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17NXlI1yqCq MYnJR|UxRTV{LkJCpOKyyqBzLkC5xsDPxE1? Mn;YNlUzOjB5Mkm=
FaDu MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnl[FEzPMLiaB?= M3LYN2lEPTB;MkWuPFnDqMLzwrCxMlE{yqEQvF2= MoP5NlUzOjB5Mkm=
SCC25 NH;hbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn6zOFjDqGh? M1;zbWlEPTB;MkCuPFbDqMLzwrCxMlA4yqEQvF2= M1nsXVI2OjJyN{K5
CAL27 M3LWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHW4fos1QMLiaB?= NV7yUnJYUUN3ME2xPE4zPMLiwsJCpFEvOTYEoN88US=> NUT2fG56OjV{MkC3Nlk>
FaDu NFS5TmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYK0POKhcA>? MknWTWM2OD14LkSzxsDDucLiMT6xN:Kh|ryP NHTNSXMzPTJ{MEeyPS=>
SCC25 NHrRWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXq3NuKhcA>? NFi2ZoJKSzVyPUiuOFHDqMLzwrCxMlEyyqEQvF2= MUeyOVIzODd{OR?=
CAL27 M2CwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXNO|LDqGh? NELSUlJKSzVyPUSuNlfDqMLzwrCxMlE1yqEQvF2= NV3KdG85OjV{MkC3Nlk>
FaDu NGjyNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fEV|czyqCq NFr2VnRKSzVyPUWuNFLDqMLzwrCxMlE2yqEQvF2= MojUNlUzOjB5Mkm=
MCF-7 NHvtcGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvwOFjDqGkEoB?= NHLKfXNFVVOR NXq2XYJuUUN3ME23MlLDqMLzwrCwMljDqM7:TR?= MYGyOVIyPjN5OB?=
T-47D NUn0b4xRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnRbVU1QMLiaNMg NFvMZm5FVVOR MoDyTWM2OD15LkhCpOKyyqByLkhCpO69VQ>? M1yzdVI2OjF4M{e4
MDA-MB-231 NHzWXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorWOFjDqGkEoB?= NYP4R5RnTE2VTx?= MVXJR|UxRTF{LklCpOKyyqBzLkFCpO69VQ>? M4W2dVI2OjF4M{e4
DU145 NWjEN25YSXCxcITvd4l{KEG|c3H5 MUCxNE0yODBizszN MUC4JIg> MXnEUXNQ NYXiUlAycW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u Mn;DNlUyPDl4OEG=
DU145 stem-like MWPBdI9xfG:|aYOgRZN{[Xl? M3W0SFExNTFyMDFOwG0> M1S1clghcA>? NG\1W5ZFVVOR NIi1VnFqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlfCNlUyPDl4OEG=
DU145 NVfiZmlGTnWwY4Tpc44hSXO|YYm= M3TM[|ExNTFyMDFOwG0> NFPaXG8zKGh? NGr3b5RFVVOR NU[wfW1qcW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYmyOVE1QTZ6MR?=
DU145 stem-like NViyOXA4TnWwY4Tpc44hSXO|YYm= MYixNE0yODBizszN NGiyXYQzKGh? MnfKSG1UVw>? MUXpcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NELFd3MzPTF2OU[4NS=>
UW228-3 M{jI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXiwMlAyNTNyMDFOwG0> MXi0PEBp NHGzbWhFVVOR M3r4dWlEPTB;MD65PeKh|ryP NHiwR2gzPTFzOUG4OS=>
NSCs NXjtbW5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX6NE4xOS1|MECg{txO NFnYV3U1QCCq MoHtSG1UVw>? NWfZOWZlUUN3ME2wMlMuO8LizszN MXeyOVEyQTF6NR?=
MKL-1  NXvKclRtTnWwY4Tpc44hSXO|YYm= M3vISlExNTFyMECgcm0> M1PsblQh\A>? NEG1VIJqdmS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gUWhENUliZYjwdoV{e2mxbh?= MUOyOVEyPjd3NB?=
MCF7 EV MXTGeY5kfGmxbjDBd5NigQ>? MmTqNVAuOTByIN88US=> MUGy5qCKcA>? Ml;CbY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> MmOwNlUxQDh{MEO=
MCF 7BMI1 MYrGeY5kfGmxbjDBd5NigQ>? MlnKNVAuOTByIN88US=> NUTUXZJvOuLCiXi= MlHZbY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> NIqxWoIzPTB6OEKwNy=>
MCF7 EV M2LvbWZ2dmO2aX;uJGF{e2G7 NV7n[VBUOTBvMUCwJO69VQ>? NWTCOGw1OuLCiXi= NF3N[nRGXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> MoPiNlUxQDh{MEO=
MCF7 BMI1 MoDzSpVv[3Srb36gRZN{[Xl? MmO4NVAuOTByIN88US=> M{PDZ|LjiImq M{HUNGVVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> MoLINlUxQDh{MEO=
HepG2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfJSYFFVVORwrC= MWLJR|UxRTNyLkG2xsDDucLiMD61NOKh|ryP MVeyOVA4QDNzMR?=
MOLT-3 MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXQSo5ITE2VT9Mg NHv3OY9KSzVyPUCuNFUyyqEEsdMgNE4xODMEoN88US=> MmG4NlUxPzh|MUG=
HT1080 NUXNbnprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGxMVExOCEQvF2= M134OlQwOjRxNEigbC=> MWjEUXNQyqB? MXvpcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? NX[5N2tpOjVyN{iwOlQ>
HT1080 MV7GeY5kfGmxbjDBd5NigQ>? M3raeFAvODByMT2xNFAh|ryP M13UXlEuOjRiaB?= MlPnSG1UV8Li M4O3RYlv\HWlZYOgdE1xPTNqc3XyNVUqKGmwIHLveIghfGmvZT2gZY5lKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= MUGyOVA4QDB4NB?=
HT1080 M3naSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zLZVAvODByMT2xNFAh|ryP MlTCNlQhcA>? M1TUU2ROW00EoB?= MW\jZZV{\XNiYX6gbY5kemWjc3WgbY4hfGinIH71cYJmeiCxZjDj[YxteyCrbjDHNk9ONCC5aHns[UBl\WO{ZXHzbY5oKFNiYX7kJGcyKHCqYYPlJINmdGy| M4LsXlI2ODd6ME[0
HD-MY-Z NYfvOGJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nuXlI1NzR6L{eyJIg> MkS5TWM2OO,:nkGwNEDPxE1? NXL0UpBDOjVyNEiyN|Y>
DOHH-2 NYjPUmJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPMNlQhcA>? NHOwcVlKSzVy78{eNVAxKM7:TR?= NHznUGkzPTB2OEKzOi=>
DOHH-2 M4rXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[0PEBp MWfJR|UxRTF7LkpCpO69VQ>? Ml7ONlUxPDh{M{[=
DOHH-2 M3L2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHiyZVE4OiCq NUTv[VNuUUN3ME21xsDPxE1? M3LwcVI2ODR6MkO2
REH MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP5c2wzPCCq M{jHOmlEPTB;MD6wNlfDqM7:TR?= MoHwNlUxPDh{M{[=
REH NVqze|VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLZOFghcA>? MmrjTWM2OD1yLkCxOOKh|ryP MkPTNlUxPDh{M{[=
REH MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTDO|IhcA>? NInIUXVKSzVyPUCuNFE2yqEQvF2= NXz4SINOOjVyNEiyN|Y>
HH NXHtT3U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnhU|lXOjRiaB?= MkDHTWM2OD1zMESuO:Kh|ryP NIn3OJgzPTB2OEKzOi=>
HH MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXYeXBDPDhiaB?= NFG1WIFKSzVyPUS4MlbDqM7:TR?= MknJNlUxPDh{M{[=
HH Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTKO|IhcA>? NFHnUWpKSzVyPUG0MlfDqM7:TR?= NVLoXnl1OjVyNEiyN|Y>
HuT-78 Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOyOEBp NE\hUYdKSzVyPUmuN:Kh|ryP NUfnUWpkOjVyNEiyN|Y>
HuT-78 NV7vcJg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\wTI41QCCq NIW4cZhKSzVyPUSuN:Kh|ryP NXqySZF[OjVyNEiyN|Y>
HuT-78 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH76N2Y4OiCq MnroTWM2OD12LkNCpO69VQ>? NGrPS3AzPTB2OEKzOi=>
OPM-2 NIfYZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSyOEBp NYDTVI86UUN3ME2yOE4yyqEQvF2= MmDoNlUxPDh{M{[=
OPM-2 NWDF[YxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnuc|c1QCCq NWW1cVZNUUN3ME20xsDPxE1? NEDnbXgzPTB2OEKzOi=>
OPM-2 NGP1em5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne3O|IhcA>? M3TSSGlEPTB;MT6zxsDPxE1? MV6yOVA1QDJ|Nh?=
RPMI-8226 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7SSYQzPCCq MlL1TWM2OD1zME[uOuKh|ryP M1HmXFI2ODR6MkO2
RPMI-8226 NYn0bHU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\UVlQ5KGh? M1;SRWlEPTB;OUGuNeKh|ryP NH7GfZQzPTB2OEKzOi=>
RPMI-8226 NFnIRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TNeVczKGh? MoCwTWM2OD1zND65xsDPxE1? MWWyOVA1QDJ|Nh?=
U-266 NV34NVBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;sWW93OjRiaB?= MUPJR|UxRTh4LkNCpO69VQ>? MUeyOVA1QDJ|Nh?=
U-266 M{XENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXK0PEBp M1e3dGlEPTB;NkiuOOKh|ryP Mln1NlUxPDh{M{[=
U-266 M2HGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUOyclE2PzJiaB?= Mo\kTWM2OD1{Nz60xsDPxE1? NYnSTFE2OjVyNEiyN|Y>
Kelly NVG4eINkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW5U29nOC1zMDFOwG0> NF72OYc4OsLiaB?= M165U2lEPTB;MT61NVjDqM7:TR?= NEK3VYUzPTByOEmwNC=>
SH-SY5Y  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUGwMVExKM7:TR?= NFXXfpY4OsLiaB?= M{PlS2lEPTB;MD63OVTDqM7:TdMg NIn6cYIzPTByOEmwNC=>
SK-N-AS NGnrRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nvS|AuOTBizszN NETZSmg4OsLiaB?= NVmwfFd4UUN3ME2xMlcyOsLizszNxsA> NYjHc3RkOjVyMEi5NFA>
SK-N-DZ M1jjcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;EUVAuOTBizszN NFfrSZc4OsLiaB?= MWTJR|UxRTVwNEi1xsDPxE1? MknKNlUxODh7MEC=
HepG2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV60POKhcA>? M2i1fGROW00EoB?= NXTKcplpUUN3ME2xN{43PcLiwsJCpFAvQTMEoN88US=> MmPZNlQ6QTZzM{[=
A549 NFjQeJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3rRXZwPDkEoHi= MlrmSG1UV8Li MkjqTWM2OD1{NEGuPeKhyrIEoEOxMlI{yqEQvF2= MlrtNlQ6QTZzM{[=
MCF7 M3\0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknvOFjDqGh? MWnEUXNQyqB? MVzJR|UxRThzLkC5xsDDucLiMUSuNlHDqM7:TR?= M4PxRlI1QTl4MUO2
HL-60  NV;SV5hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3nPVk4OsLiaB?= NWH0fI1zUUN3ME2wMlEz6oDHzszN NGnVepkzPDl7M{CxOC=>
HL-60[R] NX\4OoN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HpdFczyqCq MWfJR|UxRTNwMUNihKXPxE1? NInse5UzPDl7M{CxOC=>
MIAPACA MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnHTVUxRTFwMzFCtUAxNjB|IN88US=> NGnnRo8zPDl3M{iyNS=>
MCF-7 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIraNpNIUTVyPUCuNlUhyrFiMD6xJO69VQ>? M13RWFI1QTV|OEKx
HeLa NH7xRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\HTVUxRTBwNkSgxtEhOC52IN88US=> NVjoPIROOjR7NUO4NlE>
MO59K  NED0eI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jOT|ch\A>? NY\3bGlHUUN3ME2wMlE46oDHzszN MljhNlQ6PTN3NkG=
MO59J NYnMWXp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zHeFch\A>? NUO5[YlDUUN3ME2wMlHjiIYQvF2= M4XuelI1QTV|NU[x
ME 180 MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHi1OWg1QMLiaNMg M1HrO2lEPTB;OD65xsDDucLiMD6z5qCG|ryP MUeyOFk2OzB{Nx?=
MCF-7 M3fRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rDWFQ5yqCqwrC= NV3rcZdXUUN3ME2yN{46KMLzIECuN-KBjc7:TR?= NYDkUnA2OjR7NUOwNlc>
HeLa NYX6boFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn5bm1DPDkEoHlCpC=> M2X5VWlEPTB;ND63NUDDuSBzLkVihKXPxE1? M{CwRVI1QTV|MEK3
MDA-MB-453 Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknDOFjDqGkEoB?= NFriPW9KSzVyPUGyMlUhyrFiMD64OgKBjc7:TR?= NH2zW2QzPDl3M{CyOy=>
MDA-MB-231 M1LBS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DmU|Q5yqCqwrC= NU\3PHRKUUN3ME2yOE4zOiEEsTCyMlk16oDHzszN M3zSVlI1QTV|MEK3
PC-3 NF[xe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWe0POKhcMLi MkTITWM2OD1zND60JOKyKDNwMkRihKXPxE1? MXOyOFk2OzB{Nx?=
HT-29 NUTYXW5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;OWog1QMLiaNMg M4r4cWlEPTB;MkGuOFUhyrFiMz64O-KBjc7:TR?= MljmNlQ6PTNyMke=
BGC-823 NGT0RYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofOOFjDqGkEoB?= M{nJcmlEPTB;NEOuO|QhyrFiNT6xN-KBjc7:TR?= M33SXFI1Pzl|OEe3
HeLa MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYe0POKhcMLi MlXtTWM2OD1{MEmuPVAhyrFiMUOuOFIh6oDHzszN M2D5[|I1Pzl|OEe3
A549 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1W3OlQ5yqCqwrC= MXnJR|UxRTF|OT61OEDDuSB5LkC15qCG|ryP NWP6bnJ2OjR5OUO4O|c>
HK-2 NY\0VZk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLwOFjDqGkEoB?= M{O3S2lEPTB;OT6xO{DDuSBzLkW45qCG|ryP MYSyOFc6Ozh5Nx?=

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+30% PEG 300+H2O
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID